Ocular Therapeutix director gets new RSUs and options

Ocular Therapeutix director Merilee Raines received new equity awards.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ocular Therapeutix director Merilee Raines received new equity awards. On June 10, 2026, she was granted 14,000 restricted stock units, each representing one share of common stock, under the company’s 2021 Stock Incentive Plan.

Subject to her continued board service, these RSUs vest in full on the first anniversary of the grant date or immediately before the next annual stockholder meeting, whichever comes first. She also received stock options for 44,000 shares at an exercise price of $8.74 per share, expiring on June 9, 2036, with similar vesting conditions. Following the grant, she directly holds 60,933 shares of common stock, in addition to the new option award.

Insider Trade Summary

Grant/Award: 58,000 shares

Grant/Award 2 txns

Insider RAINES MERILEE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	44,000	$0.00	$0.00
Grant/Award	Common Stock	14,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 44,000 contracts (Direct); Common Stock — 60,933 shares (Direct)

Footnotes (2)

F1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
F2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

Key Figures

RSU grant: 14,000 RSUs Shares held after grant: 60,933 shares Stock options granted: 44,000 options +2 more

5 metrics

RSU grant 14,000 RSUs Granted June 10, 2026 under 2021 Stock Incentive Plan

Shares held after grant 60,933 shares Common stock directly held following RSU grant

Stock options granted 44,000 options Right to buy common stock granted June 10, 2026

Option exercise price $8.74 per share Conversion or exercise price for 44,000 options

Option expiration June 9, 2036 Expiration date of stock options granted

Key Terms

restricted stock units ("RSUs"), 2021 Stock Incentive Plan, Stock Option (Right to Buy), vesting

4 terms

restricted stock units ("RSUs") financial

"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

2021 Stock Incentive Plan financial

"granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vesting financial

"the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Ocular Therapeutix (OCUL) director Merilee Raines receive?

Merilee Raines received 14,000 restricted stock units and stock options for 44,000 shares. The RSUs convert into common stock, and the options have a set exercise price, expanding her long-term equity-based compensation.

When do Merilee Raines’s new Ocular Therapeutix (OCUL) RSUs vest?

The 14,000 RSUs vest 100% on the first anniversary of the June 10, 2026 grant date. Alternatively, they vest earlier immediately before the next annual stockholder meeting, if that occurs sooner, assuming she continues serving on the board.

What are the key terms of Merilee Raines’s new stock options at Ocular Therapeutix (OCUL)?

Raines received options for 44,000 shares of common stock with an $8.74 exercise price. These options vest in full on the first anniversary of the grant date or earlier before the next annual stockholder meeting and expire on June 9, 2036.

How many Ocular Therapeutix (OCUL) shares does Merilee Raines hold after these grants?

After the June 10, 2026 grant, Raines directly holds 60,933 shares of common stock. This is in addition to her new option grant covering 44,000 underlying shares, further aligning her compensation with Ocular Therapeutix’s equity performance.

Are Merilee Raines’s new equity awards at Ocular Therapeutix (OCUL) market purchases?

No. The filing shows these awards as grants under the 2021 Stock Incentive Plan, not open-market purchases. Both the RSUs and options were acquired at a reported price of $0.00 per share as part of her director compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/12/2026 - 05:19 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RAINES MERILEE

(Last)

(First)

(Middle)

C/O OCULAR THERAPEUTIX, INC.

14 CROSBY DRIVE, 3RD FLOOR

(Street)

BEDFORD

MASSACHUSETTS

01730

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/10/2026		A		14,000⁽¹⁾	A	$0	60,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$8.74	06/10/2026		A		44,000		⁽²⁾	06/09/2036	Common Stock	44,000	$0	44,000	D

Explanation of Responses:

1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.

	/s/ Todd Anderman, Attorney-in-Fact for Merilee Raines	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR